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Multiparametric Magnetic Resonance Imaging (MRI) 
(mpMRI) of the prostate consists of three parameters: 
high-resolution T2-weighted anatomical imaging (T2w), 
diffusion-weighted imaging (DWI), and dynamic contrast-
enhanced (DCE) MRI. Minimal technical requirements 
for the acquisition of dedicated prostate MR-images have 
been described in the Prostate Imaging Reporting and 
Data System (PI-RADS), which currently is in its version 
2.1 [1]. It also contains a standardized reporting system, 
which groups imaging findings on T2w, DWI, and DCE and 
yields a final categorization into a 5-point scale predicting 
the likelihood of clinically significant prostate cancer.
The diagnostic performance of mpMRI of the prostate 
using PI-RADS has been amply studied in numerous high-
quality studies during the last decade. In 2017, a meta-
analysis consisting of 21 studies, including 3857 patients, 
calculated a pooled sensitivity of 89% (range 73%–100%) 
and a pooled specificity of 73% (range 7%–100%) [2]. The 
large ranges can be explained by a number of factors. 
(1) Technical factors seem to be of minor importance, 
as a subgroup analysis did not reveal any significant 
differences between 1.5T and 3.0T scanners, nor 
between use or no use of an endorectal coil (ERC) 
[2]. Nowadays, good results are therefore also pos-
sible on state-of-the-art (strong gradients, multiple 
channels) 1.5T system without ERC, provided that 
all scan parameters are concordant with the PI-RADS 
v2.1 minimal technical requirements. 
(2) The definition of prostate cancer has an 
important impact on the diagnostic performance 
of mpMRI. International Society of Uropathology 
(ISUP) 1 cancers (Gleason 3 + 3) are well-differentiat-
ed cancers that are usually indolent and not harmful 
to the patient. But being well-differentiated, they 
resemble normal tissue, so they are difficult to 
visualize on mpMRI. ISUP 3–5 cancers (primary 
Gleason grades 4 and 5) are poorly differentiated 
cancers that are readily visible on mpMRI, whereas 
ISUP 2 cancers (Gleason 3 + 4) are indeterminate. If 
a positive mpMRI is defined as a PI-RADS 3–5, then 
68% of prostate cancers of any aggressiveness (ISUP 
1–5) will be detected, 89% of all clinically significant 
cancers (ISUP 2–5) and 96% of all highly aggressive 
cancers (ISUP 3–5) [3]. The latter findings generate 
the paradigm that a negative mpMRI (PI-RADS 1–2) 
can spare an unnecessary biopsy and that a positive 
mpMRI (PI-RADS 3–5) can be used to target a biopsy 
to the suspicious area. A meta-analysis by Moldovan 
indeed showed that mpMRI has a negative predic-
tive value of 88% (range 69%–100%) for excluding 
a clinically significant prostate cancer and another 
meta-analysis by Fütterer showed a positive pre-
dictive value range of 34%–68%, both increasing 
when highly aggressive cancers (ISUP 3–5) are to be 
detected [4, 5].
(3) A chain is of course only as strong as its weakest link. 
mpMRI can be of excellent quality, both in terms of 
technique and reporting, but its value remains zero 
when the ground truth verification is ineffec-
tive. Each time a mpMRI signals a lesion within the 
prostate, that lesion should be accurately sampled 
by a targeted biopsy approach. It has been shown 
that in-bore prostate biopsy is the optimal choice, 
followed by ultrasound-MRI fusion techniques and 
cognitive fusion (i.e. with knowledge of the location 
on MRI a biopsy is performed in the same area as 
recognized on ultrasound). However, the sensitiv-
ity differences between the three techniques were 
not statistically significant, suggesting that any 
technique can suffice when properly executed [6]. 
(4) The clinical scenario in which mpMRI is performed 
has a huge impact on its diagnostic performance, 
mainly because of the varying yields of prostate 
cancer associated with this clinical scenario. In a 
patient group with prior negative biopsy, easily de-
tectible prostate cancers have already been filtered 
away by the prior systematic biopsy, so only cancers 
that are more difficult to find with systematic biopsy 
remain, such as small or anteriorly located cancers. 
These can more easily be found with mpMRI, so 
it is not surprising that a recent Cochrane review 
confirmed that the chance of finding a cancer with 
mpMRI was 44% higher than with standard biopsy 
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in the prior negative biopsy setting, whereas only 
5% higher in the biopsy-naïve scenario [7]. Never-
theless, the European Association of Urology has 
recently updated its guidelines stating that mpMRI 
is recommended as a first line test in both the prior 
negative as in the biopsy-naïve setting. The ration-
ale, however, is different in both settings. In the 
prior negative biopsy setting, the main advantage 
is increased cancer detection, whereas in the latter, 
the main objective is to decrease the total number 
of biopsies with about 33%, while maintaining the 
number of clinically significant cancer detections 
(+2%) and decreasing the number of insignificant 
cancer detections (–8%) [7]. Similar results are now 
suggested also with biparametric MRI (bpMRI), 
consisting of T2w and DWI only, provided that 
the image quality of DWI is optimal and that this 
technique is not used for recurrence detection after 
radical prostatectomy or radiotherapy [8].
(5) Finally, the impact of expertise on the diagnostic 
results is crucial. The reported ranges in sensitivity, 
specificity, positive predictive value, and negative 
predictive value cannot be explained exclusively 
by the four mentioned reasons above. Multi-reader 
variability is a well-known and major source of per-
formance variation. The effect of initial training in 
non-experienced readers (with less than 50 case 
reads) has been nicely shown by Garcia-Reyes, with 
accuracies increasing from 74% to 88% following 
two didactic lectures with interactive case discus-
sions [9]. In a more comprehensive study, Hansen 
showed that expert readers (>1000 case reads) 
typically have higher numbers of negative mpMRIs 
(i.e. less overcalling and less biopsies) than readers 
with modest experience who turn every uncertainty 
into a positive read [10]. Experts also have higher 
positive and negative predictive values, indicating a 
higher reading confidence and precision.
Quality criteria and subsequent certification are the fastest 
way to ensure this kind of high-quality reading, similar to 
what happened in breast cancer screening. The European 
Society of Urogenital Radiology conducted a Delphi 
survey among its members to seek consensus about this 
matter. Preliminary results were that image quality should 
be optimized through compliance to PI-RADS v2.1 and 
regular self and peer assessments. Reading quality should 
equally be compliant to PI-RADS v2.1, with a percentage 
of PI-RADS 3 results lower than 25% (ideally 15%) and 
a percentage of PI-RADS 1–2 results higher than 30%. 
Histopathological feedback is mandatory (e.g. through 
MDT participation), in order to learn from both successes 
and mistakes. 
In conclusion, mpMRI is a great tool for prostate cancer 
diagnosis. It results in less (unnecessary) biopsies overall, 
increases the yield of clinically significant cancers and 
decreases the number of insignificant cancers. However, 
the scientific triumphs as reported in the literature do 
not always translate into daily practice! Urologists who 
hear or read about these triumphs expect the same 
successes in their own hospitals, but if radiologists fail 
to deliver that quality, they lose credibility and a great 
tool becomes an unreliable tool… Therefore, technical 
and reporting standardization of mpMRI is mandatory 
(as accomplished in PI-RADS v2.1), but there is also a 
need for training, expanding knowledge and maximizing 
expertise. Furthermore, quality criteria and certification 
will pave the way to constant reader quality and referral 
confidence.
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